Study on Combination Therapy for Esophageal, Gastric, or Gastro-esophageal Junction Cancer

Inclusion Criteria

• Have advanced or metastatic esophageal, gastric, or gastroesophageal junction cancer that cannot be removed by surgery.
• The cancer must have worsened after one previous treatment for metastatic disease, or if untreated, it must have progressed during or shortly after initial treatments.
• Must have a confirmed diagnosis of esophageal, gastric, or gastroesophageal junction adenocarcinoma through lab tests.
• Must have cancer that can be measured or evaluated using standard criteria.
• Must be 18 years or older.
• Must be in good overall health with a performance status of 0 or 1, meaning fully active or restricted in physically strenuous activity but ambulatory.
• Must have adequate organ function, including:
  • Neutrophil count of at least 1000/mcL.
  • Platelet count of at least 90,000/mcL.
  • Hemoglobin level of at least 8 g/dL.
  • Serum creatinine level no more than 1.5 times the upper limit of normal.
  • Liver function tests within specified limits, except for certain conditions like Gilbert's disease.
  • Albumin level of at least 3 mg/dL.

Exclusion Criteria

• Have previously received ramucirumab.
• Have received paclitaxel or docetaxel-based therapy within 6 months before joining the study.
• Have had severe immune-related side effects from certain cancer therapies.
• Have an immune deficiency or are taking immune-suppressing medications, except for specific replacement therapies.
• Have a history of gastrointestinal perforation or fistulae.
• Have active tuberculosis.
• Have active cancer spread to the brain or spinal cord.
• Have a history of lung inflammation not caused by infection.
• Have nerve damage affecting daily activities.
• Have HIV or active hepatitis B or C infections.
• Have received a live vaccine within 30 days before starting the study.
• Have psychiatric or substance abuse issues that would interfere with the study.
• Are pregnant, breastfeeding, or planning to have children during the study and for 5 months after.
• Are unwilling to provide informed consent or unable to follow the study requirements.